Research Areas - Clinical trials
Clinical trials
The scientific insight and discoveries achieved by Alimonti's team are driven by improving clinical outcomes and helping patients' health. To date, the following active Clinical trials are:
- Combination Study of AZD5069 and Enzalutamide (ACE, NCT03177187, EudraCT 2016-003141-28, PI Prof. Andrea Alimonti, Bellinzona)
- Valid Biomarkers in Blood to Predict the Response to Therapy in Prostate Cancer Patients (NCT03408964, IOSI-IOR-002, PI Prof. Andrea Alimonti, Bellinzona)
- Phase I/II Trial of Abiraterone Acetate in Combination with Tildrakizumab (anti-IL23 targeting monoclonal antibody) in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (ACTIon: NCT04458311, EudraCT 2019-003485-40, Rif. CE TI 3833, PI Prof. Andrea Alimonti, Bellinzona)
- Phase I/II Study to Assess the Safety, Tolerability and Preliminary Anti-Tumour Activity of Oral Combination Antibiotic Therapy to Modulate the Microbiome in Combination with Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (PROMIZE, EudraCT 2021-004559-18, PI Prof. Andrea Alimonti, Bellinzona)
- A pilot study to investigate the effects of lifestyle intervention on physical activity and diet in patients with metastatic prostate cancer receiving novel hormonal agents (ACTIDIET-PRO, IOR-IOSI actidiet_pro)
- Ricerca di marcatori prognostici e predittivi su tessuto tumorale in pazienti con carcinoma della prostata (Codice CESC 5170/AO/21, PI Prof. Fabrizio Dal Moro, Padova)
- Studio retrospettivo per esplorare la presenza di biomarcatori prognostici e predittivi in pazienti con carcinoma della prostata (Codice CESC 5480/AO/22, PI Prof. Angelo Paolo Dei Tos, Padova)
- A prospective observational study to assess the association between gut microbiome/use of antibiotics and response to treatments for metastatic castration resistant prostate cancer (mCRPC) (FLORA, Rif CE TI 3831)
